Side-by-side comparison of AI visibility scores, market position, and capabilities
Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.
Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.
Nasdaq IPO Feb 2026 (~$200M raised, ~$780M valuation, ticker AGMB). Positive Phase 2a data for ontunisertib in fibrostenosing Crohn's. Phase 1 data for AGMB-447 in IPF. Gut-restricted ALK5 inhibitor.
Agomab Therapeutics went public on Nasdaq in February 2026, raising approximately $200 million at an ~$780 million valuation (ticker: AGMB), becoming one of the first European biotechs to list in the US in 2026. Agomab is developing ontunisertib — the only clinical-stage gut-restricted ALK5/TGFβR1 inhibitor for fibrostenosing Crohn's disease, a severe complication where intestinal fibrosis causes strictures requiring repeated surgery. The company also has AGMB-447 in Phase 1 for idiopathic pulmonary fibrosis (IPF), using lung-restricted delivery of the same mechanism.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.